HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites

FASEB Journal

Volumn 25, Issue 5, 2011, Pages 1729-1736

  White, Rhian E ^a   Powell, David J ^b   Berry, Colin ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

HAART; Proteasome

Indexed keywords

AMPRENAVIR; DDI1 PROTEIN; FUNGAL PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; ISOVALERYL PEPSTATIN; LOPINAVIR; MICROORGANISM PROTEIN; NELFINAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ARTICLE; CELL STRUCTURE; DRUG STRUCTURE; FUNGAL STRAIN; FUNGUS CULTURE; IC 50; LEISHMANIA; MOLECULAR CLONING; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TARGETING; SACCHAROMYCES CEREVISIAE;

HIV PROTEASE INHIBITORS; INHIBITORY CONCENTRATION 50; LEISHMANIA; MOLECULAR STRUCTURE; NELFINAVIR; PROTOZOAN PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS;

LEISHMANIA MAJOR; SACCHAROMYCES CEREVISIAE;

EID: 79955663748     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-178947     Document Type: Article

References (43)

1. Hobbs, C. V., Voza, T., Coppi, A., Kirmse, B., Marsh, K., Borkowsky, W., and Sinnis, P. (2009) HIV protease inhibitors inhibit the development of preerythrocytic-stage Plasmodium parasites. J. Infect. Dis. 199, 134-141
2. Peatey, C. L., Andrews, K. T., Eickel, N., MacDonald, T., Butterworth, A. S., Trenholme, K. R., Gardiner, D. L., McCarthy, J. S., and Skinner-Adams, T. S. (2010) Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors. Antimicrob. Agents Chemother. 54, 1334-1337
3. Parikh, S., Liu, J., Sijwali, P., Gut, J., Goldberg, D. E., and Rosenthal, P. J. (2006) Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrob. Agents Chemother. 50, 2207-2209 (Pubitemid 43807545)
4. Skinner-Adams, T. S., McCarthy, J. S., Gardiner, D. L., Hilton, P. M., and Andrews, K. T. (2004) Antiretrovirals as antimalarial agents. J. Infect. Dis. 190, 1998-2000
5. Nathoo, S., Serghides, L., and Kain, K. C. (2003) Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 362, 1039-1041
6. Martins, T. M., Domingos, A., Berry, C., and Wyatt, D. M. (2006) The activity and inhibition of the food vacuole plasmepsin from the rodent malaria parasite Plasmodium chabaudi. Acta Trop. 97, 212-218
7. Andrews, K. T., Fairlie, D. P., Madala, P. K., Ray, J., Wyatt, D. M., Hilton, P. M., Melville, L. A., Beattie, L., Gardiner, D. L., Reid, R. C., Stoermer, M. J., Skinner-Adams, T., Berry, C., and McCarthy, J. S. (2006) Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 50, 639-648 (Pubitemid 43190977)
8. Skinner-Adams, T. S., Andrews, K. T., Melville, L., McCarthy, J., and Gardiner, D. L. (2007) Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 51, 759-762
9. Lek-Uthai, U., Suwanarusk, R., Ruengweerayut, R., Skinner-Adams, T. S., Nosten, F., Gardiner, D. L., Boonma, P., Piera, K. A., Andrews, K. T., Machunter, B., McCarthy, J. S., Anstey, N. M., Price, R. N., and Russell, B. (2008) Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob. Agents Chemother. 52, 2435-2441 (Pubitemid 351915673)
10. Redmond, A. M., Skinner-Adams, T., Andrews, K. T., Gardiner, D. L., Ray, J., Kelly, M., and McCarthy, J. S. (2007) Antimalarial activity of sera from subjects taking HIV protease inhibitors. AIDS 21, 763-765 (Pubitemid 46568635)
11. Cassone, A., De Bernardis, F., Torosantucci, A., Tacconelli, E., Tumbarello, M., and Cauda, R. (1999) In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180, 448-453 (Pubitemid 30256327)
12. Cassone, A., Tacconelli, E., De Bernardis, F., Tumbarello, M., Torosantucci, A., Chiani, P., and Cauda, R. (2002) Antiretroviral therapy with protease inhibitors has an early, immune reconstitution- independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J. Infect. Dis. 185, 188-195 (Pubitemid 34056442)
13. Cassone, A., and Cauda, R. (2002) HIV proteinase inhibitors: do they really work against Candida in a clinical setting? Trends Microbiol. 10, 177-178 (Pubitemid 34242954)
14. Skrbec, D., and Romeo, D. (2002) Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease. Biochem. Biophys. Res. Commun. 297, 1350-1353 (Pubitemid 35216396)
15. Savoia, D., Allice, T., and Tovo, P. A. (2005) Antileishmanial activity of HIV protease inhibitors. Int. J. Antimicrob. Agents 26, 92-94
16. Trudel, N., Garg, R., Messier, N., Sundar, S., Ouellette, M., and Tremblay, M. J. (2008) Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J. Infect. Dis. 198, 1292-1299
17. Santos, L. O., Marinho, F. A., Altoe, E. F., Vitorio, B. S., Alves, C. R., Britto, C., Motta, M. C., Branquinha, M. H., Santos, A. L., and d'Avila-Levy, C. M. (2009) HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PLoS One 4, e4918
18. Pozio, E., and Morales, M. A. (2005) The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol. 21, 58-63
19. Barrett, A. J., Rawlings, N. D., and Woessner, J. F. (2004) Handbook of Proteolytic Enzymes, Vol. 1, Elsevier Academic, London
20. Wilson, S. I., Phylip, L. H., Mills, J. S., Gulnik, S. V., Erickson, J. W., Dunn, B. M., and Kay, J. (1997) Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition. Biochim. Biophys. Acta 1339, 113-125 (Pubitemid 27193319)
21. Parikh, S., Gut, J., Istvan, E., Goldberg, D. E., Havlir, D. V., and Rosenthal, P. J. (2005) Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49, 2983-2985 (Pubitemid 40917621)
22. Coombs, G. H., Goldberg, D. E., Klemba, M., Berry, C., Kay, J., and Mottram, J. C. (2001) Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17, 532-537
23. He, Z., Chen, L., You, J., Qin, L., and Chen, X. (2010) In vitro interactions between antiretroviral protease inhibitors and artemisinin endoperoxides against Plasmodium falciparum. Int. J. Antimicrob. Agents 35, 191-193
24. He, Z., Chen, L., You, J., Qin, L., and Chen, X. (2009) Antiretroviral protease inhibitors potentiate chloroquine anti-malarial activity in malaria parasites by regulating intracellular glutathione metabolism. Exp. Parasitol. 123, 122-127
25. He, Z., Qin, L., Chen, L., Peng, N., You, J., and Chen, X. (2008) Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo. Antimicrob. Agents Chemother. 52, 2653-2656 (Pubitemid 351915702)
26. Alves, C. R., Corte-Real, S., Bourguignon, S. C., Chaves, C. S., and Saraiva, E. M. (2005) Leishmania amazonensis: early proteinase activities during promastigote-amastigote differentiation in vitro. Exp. Parasitol. 109, 38-48
27. Valdivieso, E., Dagger, F., and Rascon, A. (2007) Leishmania mexicana: identification and characterization of an aspartyl proteinase activity. Exp. Parasitol. 116, 77-82 (Pubitemid 46412309)
28. Krylov, D. M., and Koonin, E. V. (2001) A novel family of predicted retroviral-like aspartyl proteases with a possible key role in eukaryotic cell cycle control. Curr. Biol. 11, R584-587
29. Gabriely, G., Kama, R., Gelin-Licht, R., and Gerst, J. E. (2008) Different domains of the UBL-UBA ubiquitin receptor, Ddi1/ Vsm1, are involved in its multiple cellular roles. Mol. Biol. Cell 19, 3625-3637
30. Fatimababy, A. S., Lin, Y. L., Usharani, R., Radjacommare, R., Wang, H. T., Tsai, H. L., Lee, Y., and Fu, H. (2010) Cross-species divergence of the major recognition pathways of ubiquitylated substrates for ubiquitin/26S proteasome-mediated proteolysis. FEBS J. 277, 796-816
31. White, R. E., Dickinson, J. R., Semple, C. A. M., Powell, D. J., and Berry, C. (2011) The retroviral proteinase active site and the N-terminus of Ddi1 are required for repression of protein secretion. FEBS Lett. 585, 139-142
32. Melcher, K. (2000) A modular set of prokaryotic and eukaryotic expression vectors. Anal. Biochem. 277, 109-120
33. Ito, H., Fukuda, Y., Murata, K., and Kimura, A. (1983) Transformation of intact yeast cells treated with alkali cations. J. Bacteriol. 153, 163-168 (Pubitemid 13119852)
34. Lustgarten, V., and Gerst, J. E. (1999) Yeast VSM1 encodes a v-SNARE binding protein that may act as a negative regulator of constitutive exocytosis. Mol. Cell. Biol. 19, 4480-4494
35. Ivantsiv, Y., Kaplun, L., Tzirkin-Goldin, R., Shabek, N., and Raveh, D. (2006) Unique role for the UbL-UbA protein Ddi1 in turnover of SCFUfo1 complexes. Mol. Cell. Biol. 26, 1579-1588
36. Diaz-Martinez, L. A., Kang, Y., Walters, K. J., and Clarke, D. J. (2006) Yeast UBL-UBA proteins have partially redundant functions in cell cycle control. Cell. Div. 1, 28
37. Kaplun, L., Tzirkin, R., Bakhrat, A., Shabek, N., Ivantsiv, Y., and Raveh, D. (2005) The DNA damage-inducible UbL-UbA protein Ddi1 participates in Mec1-mediated degradation of Ho endonuclease. Mol. Cell. Biol. 25, 5355-5362 (Pubitemid 40853573)
38. Bertolaet, B. L., Clarke, D. J., Wolff, M., Watson, M. H., Henze, M., Divita, G., and Reed, S. I. (2001) UBA domains of DNA damage-inducible proteins interact with ubiquitin. Nat. Struct. Biol. 8, 417-422 (Pubitemid 32381288)
39. Valdivieso, E., Rangel, A., Moreno, J., Saugar, J. M., Canavate, C., Alvar, J., and Dagger, F. (2010) Effects of HIV aspartylproteinase inhibitors on Leishmania sp. Exp. Parasitol. 126, 557-563
40. Rogers, B., Decottignies, A., Kolaczkowski, M., Carvajal, E., Balzi, E., and Goffeau, A. (2001) The pleitropic drug ABC transporters from Saccharomyces cerevisiae. J. Mol. Microbiol. Biotechnol. 3, 207-214
41. Andre, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B. L., Jr., Cerundolo, V., Bonneville, M., Jotereau, F., Zinkernagel, R. M., and Lotteau, V. (1998) An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. U. S. A. 95, 13120-13124 (Pubitemid 28509534)
42. Piccinini, M., Rinaudo, M. T., Anselmino, A., Buccinna, B., Ramondetti, C., Dematteis, A., Ricotti, E., Palmisano, L., Mostert, M., and Tovo, P. A. (2005) The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir. Ther. 10, 215-223
43. Piccinini, M., Rinaudo, M. T., Chiapello, N., Ricotti, E., Baldovino, S., Mostert, M., and Tovo, P. A. (2002) The human 26S proteasome is a target of antiretroviral agents. AIDS 16, 693-700